Pnc Financial Services Group, Inc. Macrogenics Inc Transaction History

Pnc Financial Services Group, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$9.77 - $21.47 $332 - $729	34 Added 680.0%	39 $0
Q4 2023 Feb 09, 2024	BUY	$4.48 - $10.11 $22 - $50	5 New	5 $0
Q1 2022 May 12, 2022	SELL	$8.12 - $16.9 $129 - $270	-16 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$15.91 - $21.88 $9,530 - $13,106	-599 Reduced 97.4%	16 $0
Q4 2020 Feb 12, 2021	BUY	$19.41 - $26.0 $11,626 - $15,574	599 Added 3743.75%	615 $14,000
Q3 2020 Nov 06, 2020	SELL	$24.69 - $31.6 $74 - $94	-3 Reduced 15.79%	16 $0
Q1 2020 May 08, 2020	SELL	$4.28 - $12.11 $954 - $2,700	-223 Reduced 92.15%	19 $0
Q4 2019 Feb 07, 2020	BUY	$7.95 - $12.27 $1,772 - $2,736	223 Added 1173.68%	242 $2,000
Q3 2019 Nov 08, 2019	SELL	$12.44 - $17.48 $111 - $157	-9 Reduced 32.14%	19 $0
Q2 2019 Aug 09, 2019	SELL	$14.51 - $19.71 $1,233 - $1,675	-85 Reduced 75.22%	28 $0
Q1 2019 May 10, 2019	BUY	$11.11 - $25.6 $955 - $2,201	86 Added 318.52%	113 $0
Q2 2018 Aug 10, 2018	BUY	$19.78 - $24.67 $375 - $468	19 Added 237.5%	27 $0
Q3 2017 Nov 13, 2017	BUY	$15.52 - $18.94 $124 - $151	8	8 $0

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.